Organovo Stock Forecast, Price & News

Organovo's stock was trading at $5.20 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ONVO stock has increased by 38.5% and is now trading at $7.20.
View which stocks have been most impacted by COVID-19.

Organovo is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Organovo.

Organovo Holdings Inc (NASDAQ:ONVO) issued its quarterly earnings results on Monday, August, 10th. The medical research company reported ($0.40) EPS for the quarter. Organovo had a negative return on equity of 54.41% and a negative net margin of 798.68%.
View Organovo's earnings history.

Organovo shares reverse split on the morning of Wednesday, August 19th 2020. The 1-20 reverse split was announced on Monday, August 17th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 18th 2020. An investor that had 100 shares of Organovo stock prior to the reverse split would have 5 shares after the split.

Organovo saw a decrease in short interest in August. As of August 31st, there was short interest totaling 124,100 shares, a decrease of 90.9% from the August 15th total of 1,370,000 shares. Based on an average daily trading volume, of 77,900 shares, the days-to-cover ratio is currently 1.6 days. Approximately 1.9% of the company's stock are short sold.
View Organovo's Short Interest.

Some companies that are related to Organovo include GENFIT S A/ADR (GNFT), Axcella Health (AXLA), Ayala Pharmaceuticals (AYLA), Fennec Pharmaceuticals (FENC), LogicBio Therapeutics (LOGC), INmune Bio (INMB), Applied Genetic Technologies (AGTC), Cidara Therapeutics (CDTX), Erytech Pharma (ERYP), La Jolla Pharmaceutical (LJPC), Gritstone Oncology (GRTS), X4 Pharmaceuticals (XFOR), Champions Oncology (CSBR), Solid Biosciences (SLDB) and Windtree Therapeutics (WINT).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Aerojet Rocketdyne (AJRD), Blackstone Group (BX), LADENBURG THALM/SH SH (LTS), Advanced Micro Devices (AMD), Exelixis (EXEL), Novavax (NVAX), Micron Technology (MU) and Opko Health (OPK).

Organovo trades on the NASDAQ under the ticker symbol "ONVO."

Organovo's stock is owned by a variety of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (7.50%), WINTON GROUP Ltd (0.18%), Jane Street Group LLC (0.10%), Avantax Advisory Services Inc. (0.08%), UBS Group AG (0.07%) and Commonwealth Equity Services LLC (0.07%).
View institutional ownership trends for Organovo.

ONVO stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., WINTON GROUP Ltd, and Commonwealth Equity Services LLC.
View insider buying and selling activity for Organovo.

ONVO stock was acquired by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Avantax Advisory Services Inc., and UBS Group AG.
View insider buying and selling activity for Organovo.

Shares of ONVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ONVO stock can currently be purchased for approximately $7.20.

Organovo has a market capitalization of $47.02 million and generates $2.20 million in revenue each year. Organovo employs 70 workers across the globe.

The official website for Organovo is www.organovo.com.

Organovo's mailing address is 440 STEVENS AVENUE SUITE 200, SOLANA BEACH CA, 92075. The medical research company can be reached via phone at 858-224-1000 or via email at [email protected]